HUP0301625A3 - 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions - Google Patents

1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions

Info

Publication number
HUP0301625A3
HUP0301625A3 HU0301625A HUP0301625A HUP0301625A3 HU P0301625 A3 HUP0301625 A3 HU P0301625A3 HU 0301625 A HU0301625 A HU 0301625A HU P0301625 A HUP0301625 A HU P0301625A HU P0301625 A3 HUP0301625 A3 HU P0301625A3
Authority
HU
Hungary
Prior art keywords
preparation
oxadiazine
inhibitors
copper
compounds
Prior art date
Application number
HU0301625A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of HUP0301625A2 publication Critical patent/HUP0301625A2/hu
Publication of HUP0301625A3 publication Critical patent/HUP0301625A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HU0301625A 2000-07-05 2001-07-04 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions HUP0301625A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21634100P 2000-07-05 2000-07-05
PCT/FI2001/000637 WO2002002541A2 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases

Publications (2)

Publication Number Publication Date
HUP0301625A2 HUP0301625A2 (hu) 2003-11-28
HUP0301625A3 true HUP0301625A3 (en) 2005-04-28

Family

ID=22806663

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0301625A HUP0301625A3 (en) 2000-07-05 2001-07-04 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions
HU0301336A HUP0301336A3 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0301336A HUP0301336A3 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions

Country Status (14)

Country Link
US (2) US6624202B2 (enExample)
EP (2) EP1301495A2 (enExample)
JP (2) JP2004502682A (enExample)
CN (2) CN1450997A (enExample)
AU (3) AU2001282163B2 (enExample)
CA (2) CA2414799A1 (enExample)
HU (2) HUP0301625A3 (enExample)
IL (2) IL153767A0 (enExample)
NO (2) NO20026283L (enExample)
NZ (2) NZ523464A (enExample)
PL (2) PL360353A1 (enExample)
RU (2) RU2003103291A (enExample)
WO (2) WO2002002541A2 (enExample)
ZA (2) ZA200300063B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
TWI336696B (en) 2003-01-27 2011-02-01 Astellas Pharma Inc Thiazole derivatives
KR20120045062A (ko) * 2003-03-31 2012-05-08 가부시키가이샤 아루떼꾸 우에노 혈관 과투과 질환의 치료방법
US7499847B2 (en) 2003-05-26 2009-03-03 Biotie Therapies Corporation Crystalline VAP-1 and uses thereof
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
CA2549029A1 (en) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
EP1791835A2 (en) * 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8426587B2 (en) * 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2357252A4 (en) 2008-09-03 2012-05-16 Univ Barcelona Autonoma METHOD AND COMPOSITIONS FOR TREATING AND DIAGNOSIS OF A HEMORRHAGIC CONVERSION
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
RU2010145439A (ru) 2010-11-08 2012-05-20 Виктор Вениаминович Тец (RU) Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
KR101879011B1 (ko) * 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
RU2595868C1 (ru) 2015-03-27 2016-08-27 Виктор Вениаминович Тец Лекарственное средство с гепатопротекторной активностью
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
US20180360808A1 (en) 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377345A (en) * 1966-09-23 1968-04-09 Dow Chemical Co Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof
US3486916A (en) 1966-12-22 1969-12-30 William A Cordon Cement mixes and the production of articles therefrom
SE320311B (enExample) 1968-07-15 1970-02-02 Mo Och Domsjoe Ab
WO1993023023A1 (en) * 1992-05-15 1993-11-25 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US5413634A (en) 1993-08-06 1995-05-09 Arco Chemical Technology, L.P. Cement composition
CA2117585C (en) 1993-09-14 2001-06-05 Edward T. Shawl Cement composition
WO1996006058A1 (en) 1994-08-25 1996-02-29 W.R. Grace & Co.-Conn. Shrinkage reduction cement composition
US5618344A (en) 1995-03-06 1997-04-08 W. R. Grace & Co.-Conn. Cement composition
US5556460A (en) 1995-09-18 1996-09-17 W.R. Grace & Co.-Conn. Drying shrinkage cement admixture
US5603760A (en) 1995-09-18 1997-02-18 W. R. Grace & Co.-Conn. Cement admixture capable of inhibiting drying shrinkage and method of using same
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂

Also Published As

Publication number Publication date
NZ523464A (en) 2003-10-31
CA2414807A1 (en) 2002-01-10
NO20026282D0 (no) 2002-12-30
US20040106654A1 (en) 2004-06-03
HUP0301336A3 (en) 2005-04-28
ZA200300063B (en) 2003-07-22
ZA200300064B (en) 2003-07-22
IL153766A0 (en) 2003-07-06
JP2004501962A (ja) 2004-01-22
EP1301495A2 (en) 2003-04-16
US20020173521A1 (en) 2002-11-21
AU8216301A (en) 2002-01-14
NO20026283L (no) 2003-02-28
CN1450998A (zh) 2003-10-22
CA2414799A1 (en) 2002-01-10
AU2001282162A1 (en) 2002-01-14
AU2001282163B2 (en) 2004-12-09
PL360374A1 (en) 2004-09-06
NO20026282L (no) 2003-03-03
WO2002002541A3 (en) 2002-04-18
CN1450997A (zh) 2003-10-22
EP1313718A2 (en) 2003-05-28
WO2002002090A2 (en) 2002-01-10
RU2003103286A (ru) 2004-08-20
RU2003103291A (ru) 2005-01-27
IL153767A0 (en) 2003-07-06
NZ523463A (en) 2004-06-25
WO2002002090A3 (en) 2002-05-16
US6624202B2 (en) 2003-09-23
HUP0301336A2 (hu) 2003-08-28
NO20026283D0 (no) 2002-12-30
JP2004502682A (ja) 2004-01-29
WO2002002541A2 (en) 2002-01-10
HUP0301625A2 (hu) 2003-11-28
PL360353A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
HUP0301336A3 (en) Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions
HUP0401097A3 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases, process for their preparation and pharmaceutical compositions containing them
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0200572A2 (en) Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use
HUP0203669A3 (en) Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0302487A3 (en) New mandelic acid derivatives and their use as throbin inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0301683A3 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral indopeptidase, their intermediates, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300148A3 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0204229A3 (en) Compositions oral opioid formulations, compositions process for their preparation and their use
HUP0302793A3 (en) N-substituted aniline derivatives useful as phosphodiesterase 4 inhibitors, pharmaceutical compositions containing them and process for their preparations
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
HUP0300741A3 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0301069A3 (en) Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0303133A3 (en) Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical and process for their preparation
IL145429A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
AP2002002575A0 (en) Compounds having hypolupedemic and hypocholestermic activities process for their preparation and pharmaceutical compositions containing them
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
MXPA05011496A (es) Derivados de azabiciclononeno.
HUP0302723A3 (en) Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished